Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En virkelig verden, multicenter, prospektiv, observationsundersøgelse for PNH i Kina (ReWoPNH)

22. september 2026 opdateret af: AstraZeneca

En virkelig verden, multicenter, prospektiv, observationel undersøgelse for paroxysmal natlig hæmoglobinuri (PNH) i Kina

As a rare disease listed in the First Catalogue of Rare Diseases in China (National Health Commission of the People's Republic of China, 2019), PNH is poorly studied in China subse-quently leading to the inadequate elucidation of disease characteristics and clinical outcomes. Eculizumab was recently approved by NMPA. The availability of Eculizumab in China pro-vides people living with PNH with a new treatment option that can reduce disease symptoms and prevent the dysregulated complement system from causing further damage. A Phase Ⅳ study is necessary to understand the natural history of disease and the clinical outcomes with different medical interventions.

Studieoversigt

Status

Afsluttet

Betingelser

Detaljeret beskrivelse

Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-rare and life-threatening acquired disorder of the pluripotent hematopoietic stem cell and therefore can affect erythrocytes, leukocytes, thrombocytes and probably some endothelial cells. These hematopoietic stem cells have acquired a somatic mutation in the phosphatidylinositol glycan class A (PIG-A) This gene is required for the synthesis of the glycosyl phosphatidyl-inositol (GPI) anchor, which is necessary to attach some proteins to the blood cell membrane. Therefore, a lack of two important complement regulatory proteins is observed on the cell surface: 'decay-accelerating factor' (DAF), also called 'CD55' and 'membrane inhibitor of reactive lysis' (MIRL), also called 'CD59' Thus, red blood cells are more vulnerable to the attack by the complement activation product MAC (complement membrane attack complex). This leads to a complement-mediated intravascular hemolysis. The predisposition of venous thrombosis, hemolytic anemia, complete thrombocytopenia, and thrombosis are the three main characteristics of the disease. Its incidence is not really known but estimated at 0.1~0.6/100 000 per-sons/yr, and prevalence is estimated at 1~4 cases/100,000 persons/yr. PNH was listed in the First Catalogue of Rare Diseases in China, and its incidence was previously reported to be 1/100,000 persons/year, peak onset age 20~40 years.

PNH can be classified into 3 different forms: classical PNH, PNH associated with aplastic anemia (PNH-AA), and subclinical PNH, based on clinical features, bone marrow characteristics, and the size of the mutant clone. The traditional treatment of PNH is still aimed at "protecting" the PNH clone, reducing complement attack and destruction, and alleviating hemolysis with symptomatic supportive therapy. In acute hemolytic episodes, could be administered adrenal glucocorticoids, complemented by cell membrane stabilizers, folic acid, and alkaline drugs. In case of PNH-AA syndrome, treatment with androgens and immunosuppressants may be used; anticoagulation and heparin therapy should be given for the occurrence of thrombosis; other symptomatic supportive treatments include transfusion of red blood cells and platelets if necessary as well as antibacterial drugs in case of infection. Bone marrow transplantation is the only curative therapy for PNH presupposes, but patient need to achieve complete remission with chemotherapy first and a suitable donor is needed.

Besides supportive care, global guidance/consensus also recommend C5 complement inhibitor Eculizumab as a treatment method, and its use could significantly improve 5-year survival rate to 95.5%. Eculizumabis a humanized, first-in-class, anti-C5 antibody that binds with high affinity to C5 and blocks the terminal complement-C5a and C5b-9 formation, reducing the chronic uncontrolled complement activation and its consequences. Eculizumab has been approved for PNH by National Medical Products Administration in August, 2022.

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

724

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Hangzhou, Kina
        • Research Site
    • Anhui
      • Hefei, Anhui, Kina, 230002
        • Research Site
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100000
        • Research Site
      • Beijing, Beijing Municipality, Kina, 100044
        • Research Site
    • Guangdong
      • Guangzhou, Guangdong, Kina, 510080
        • Research Site
      • Guangzhou, Guangdong, Kina, 510180
        • Research Site
      • Guangzhou, Guangdong, Kina, 510515
        • Research Site
    • Guangxi
      • Nanning, Guangxi, Kina, 530021
        • Research Site
    • Guizhou
      • Guiyang, Guizhou, Kina, 550004
        • Research Site
    • Hebei
      • Shijiazhuang, Hebei, Kina, 050000
        • Research Site
    • Heilongjiang
      • Harbin, Heilongjiang, Kina, 150001
        • Research Site
    • Henan
      • Zhengzhou, Henan, Kina, 450003
        • Research Site
      • Zhengzhou, Henan, Kina, 450052
        • Research Site
      • Zhengzhou, Henan, Kina, 463599
        • Research Site
    • Hubei
      • Wuhan, Hubei, Kina, 430030
        • Research Site
      • Wuhan, Hubei, Kina, 430000
        • Research Site
    • Hunan
      • Changsha, Hunan, Kina, 410008
        • Research Site
      • Changsha, Hunan, Kina, 410005
        • Research Site
    • Jiangsu
      • Nanjing, Jiangsu, Kina, 210029
        • Research Site
      • Nantong, Jiangsu, Kina, 226001
        • Research Site
      • Xuzhou, Jiangsu, Kina, 221002
        • Research Site
    • Jiangxi
      • Nanchang, Jiangxi, Kina, 330006
        • Research Site
      • Nanchang, Jiangxi, Kina, 330008
        • Research Site
    • Jilin
      • Changchun, Jilin, Kina, 130021
        • Research Site
    • Liaoning
      • Shenyang, Liaoning, Kina, 110001
        • Research Site
    • Shandong
      • Jinan, Shandong, Kina, 250000
        • Research Site
      • Qingdao, Shandong, Kina, 266000
        • Research Site
      • Zibo, Shandong, Kina, 255090
        • Research Site
    • Shangdong
      • Linyi, Shangdong, Kina, 276034
        • Research Site
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200040
        • Research Site
      • Shanghai, Shanghai Municipality, Kina, 200336
        • Research Site
    • Shanxi
      • Taiyuan, Shanxi, Kina, 030000
        • Research Site
      • Xi’an, Shanxi, Kina, 710061
        • Research Site
      • Xi’an, Shanxi, Kina, 710068
        • Research Site
    • Sichuan
      • Chengdu, Sichuan, Kina, 610041
        • Research Site
      • Chengdu, Sichuan, Kina, 610072
        • Research Site
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Kina, 300020
        • Research Site
      • Tianjin, Tianjin Municipality, Kina, 300052
        • Research Site
      • Tianjin, Tianjin Municipality, Kina, 300190
        • Research Site
    • Yunnan
      • Kunming, Yunnan, Kina, 650034
        • Research Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Barn
  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Study Population:

Number of patients (estimate): 1000; Inclusion Criteria

  1. Patients of any age;
  2. Diagnosed PNH with detected proportion of PNH clone cells of at least 1%;
  3. Patient or patient's family must be willing and able to give written informed consent.

Exclusion Criteria

  1. Current or previous treatment with a non-eculizumab complement inhibitor;
  2. Patients in other PNH clinical trials.
  3. Unable to give written informed consent.

Beskrivelse

Inclusion Criteria

  1. Patients of any age;
  2. Diagnosed PNH with detected proportion of PNH clone cells of at least 1%;
  3. Patient or patient's family must be willing and able to give written informed consent.

Exclusion Criteria

  1. Current or previous treatment with a non-eculizumab complement inhibitor;
  2. Patients in other PNH clinical trials.
  3. Unable to give written informed consent.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Hemolysis:Concentration of LDH changes at each visit from base-line, of all patients
Tidsramme: 12 months

To characterize the progression of PNH

12 months
Number and percentage of patients with thrombosis within follow-up
Tidsramme: 12 months

To characterize the progression of PNH

12 months
average number of units of packed RBCs transfused per month, of all patients
Tidsramme: 12 months

To characterize the progression of PNH

12 months
Number and percentage of patients with renal failure within follow-up
Tidsramme: 12 months

To characterize the progression of PNH

12 months
Number and percentage of patients with pulmonary hypertension within follow-up
Tidsramme: 12 months

To characterize the progression of PNH

12 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number and percentage of patients with each symptom of interest within follow-up
Tidsramme: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Demographics at baseline of all patients
Tidsramme: baseline

To describe clinical characteristics of patients with PNH in China

baseline
Number and percentage of patients receiving each type of treatment method at baseline and each visit within follow up, including glucocorticoid, red blood cell transfusion, other supportive treatment, bone marrow transplant, eculizumab, of all patients
Tidsramme: 12 months

To describe the treatment pattern of PNH in China

12 months
All serious adverse events (SAEs)of PNH among eculizumab-treated patients
Tidsramme: 12 months

To describe the safety of Eculizumab treatment via Serious Adverse Events

12 months
Standard descriptive statistics of pregnancy status
Tidsramme: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Standard descriptive statistics of lactation status
Tidsramme: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Standard descriptive statistics of PNH classification
Tidsramme: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Standard descriptive statistics of flow cytometry results
Tidsramme: 12 months

To describe clinical characteristics of patients with PNH in China

12 months

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Concentration of LDH changes at each visit from base-line of PNH among eculizumab-treated patients
Tidsramme: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
Number and percentage of patients with thrombosis within follow up among eculizumab-treated patients
Tidsramme: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
average number of units of packed RBCs transfused per month within 12 months v
Tidsramme: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
Number and percentage of patients with renal failure within follow up among eculizumab-treated patients
Tidsramme: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
Number and percentage of patients with pulmonary hypertension (PH) within follow up among eculizumab-treated patients
Tidsramme: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

10. november 2023

Primær færdiggørelse (Faktiske)

3. december 2025

Studieafslutning (Faktiske)

3. december 2025

Datoer for studieregistrering

Først indsendt

30. oktober 2023

Først indsendt, der opfyldte QC-kriterier

23. november 2023

Først opslået (Faktiske)

4. december 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

24. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

22. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Andre undersøgelses-id-numre

  • D7414R00001

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

IPD-delingstidsramme

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD-delingsadgangskriterier

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .